Skip to main content

Advertisement

SpringerLink
Log in

Altered expression of farnesyl pyrophosphate synthase in prostate cancer: evidence for a role of the mevalonate pathway in disease progression?

  • Original Article
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Background

Preclinical studies demonstrated effects of drugs inhibiting the mevalonate pathway including nitrogen-containing bisphosphonates (N-BPs) and statins on tumor growth and progression. The exact role of this pathway in prostate cancer (PC) has not been identified yet. Herein, we evaluate the expression of farnesyl pyrophosphate synthase (FPPS), the key enzyme of the mevalonate pathway, in PC.

Patients and methods

Prostate cancer (PC) and benign prostate tissue of 114 men who underwent radical prostatectomy were constructed to a tissue microarray. Immunohistochemical staining of FPPS was quantified by the Remmele/Stegner immunoreactivity-score. Patients’ clinical follow-up was assessed. IRS was correlated to pathological and clinical data. The impact of FPPS expression on clinical course was assessed univariate and multivariate.

Results

Mean IRS in PC and benign tissue was 5.7 (95% CI 5.0–6.5) and 2.6 (2.1–3.0, p < 0.0001). Mean IRS in PC tissue of patients with organ-confined and locally advanced disease (pT ≥ 3) was 5.09 (4.22–5.96) and 6.87 (5.57–8.17, p = 0.035). IRS of PC tissue significantly correlated with Gleason score (p = 0.03). Patients with PC tissue IRS >3 showed shorter recurrence-free survival compared to the remaining (p = 0.01). Increased FPPS expression is an independent risk factor for early biochemical recurrence (p = 0.032).

Conclusions

This is the first study on FPPS in PC specimens. The association of FPPS with established histopathological risk parameters and biochemical recurrence implicates a contribution of the mevalonate pathway to PC progression. Further functional analysis is required to explore the role of this pathway in PC and to investigate whether FPPS expression affects the response of PC cells to N-BPs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Roy M, Kung HJ, Ghosh PM (2011) Statins and prostate cancer: role of cholesterol inhibition versus prevention of small GTP-binding proteins. Am J Cancer Res 1(4):542–561

    PubMed  CAS  Google Scholar 

  2. Russell RG (2011) Bisphosphonates: the first 40 years. Bone 49(1):2–19. doi:10.1016/j.bone.2011.04.022

    Article  PubMed  CAS  Google Scholar 

  3. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13(4):581–589. doi:10.1359/jbmr.1998.13.4.581

    Article  PubMed  CAS  Google Scholar 

  4. Clezardin P (2011) Bisphosphonates’ antitumor activity: an unravelled side of a multifaceted drug class. Bone 48(1):71–79. doi:10.1016/j.bone.2010.07.016

    Article  PubMed  CAS  Google Scholar 

  5. Farley SJ (2010) Prostate cancer: time to trial statins? Nat Rev Urol 7(7):359. doi:10.1038/nrurol.2010.85

    Article  PubMed  Google Scholar 

  6. Saylor PJ, Lee RJ, Smith MR (2011) Emerging therapies to prevent skeletal morbidity in men with prostate cancer. J Clin Oncol 29(27):3705–3714. doi:10.1200/JCO.2010.34.4994

    Article  PubMed  Google Scholar 

  7. Coxon JP, Oades GM, Kirby RS, Colston KW (2004) Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int 94(1):164–170. doi:10.1111/j.1464-4096.2004.04831.xBJU4831

    Article  PubMed  CAS  Google Scholar 

  8. Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ, Calle EE (2007) Cholesterol-lowering drugs and advanced prostate cancer incidence in a large US cohort. Cancer Epidemiol Biomarkers Prev 16(11):2213–2217. doi:10.1158/1055-9965.EPI-07-0448

    Article  PubMed  CAS  Google Scholar 

  9. Hamilton RJ, Banez LL, Aronson WJ, Terris MK, Platz EA, Kane CJ, Presti JC Jr, Amling CL, Freedland SJ (2010) Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the shared equal access regional cancer hospital (SEARCH) database. Cancer 116(14):3389–3398. doi:10.1002/cncr.25308

    Article  PubMed  CAS  Google Scholar 

  10. Merseburger AS, Anastasiadis AG, Hennenlotter J, Schilling D, Simon P, Machtens SA, Serth J, Stenzl A, Kuczyk MA (2006) Tissue microarrays: applications in urological cancer research. World J Urol 24(5):579–584. doi:10.1007/s00345-006-0103-1

    Article  PubMed  CAS  Google Scholar 

  11. Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8(3):138–140

    PubMed  CAS  Google Scholar 

  12. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, Heidenreich A (2011) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 59(4):572–583. doi:10.1016/j.eururo.2011.01.025

    Article  PubMed  Google Scholar 

  13. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rucklinger E, Greil R, Marth C (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360(7):679–691. doi:10.1056/NEJMoa0806285

    Article  PubMed  CAS  Google Scholar 

  14. Morgan C, Lewis PD, Jones RM, Bertelli G, Thomas GA, Leonard RC (2007) The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer. Acta Oncol 46(5):669–677. doi:10.1080/02841860600996447

    Article  PubMed  CAS  Google Scholar 

  15. Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE, Holen I (2005) Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 113(3):364–371. doi:10.1002/ijc.20602

    Article  PubMed  CAS  Google Scholar 

  16. Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, Clezardin P (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62(22):6538–6544

    PubMed  CAS  Google Scholar 

  17. Sarker D, Reid AH, Yap TA, de Bono JS (2009) Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 15(15):4799–4805. doi:10.1158/1078-0432.CCR-08-0125

    Article  PubMed  CAS  Google Scholar 

  18. Lin JF, Lin YC, Lin YH, Tsai TF, Chou KY, Chen HE, Hwang TI (2011) Zoledronic acid induces autophagic cell death in human prostate cancer cells. J Urol 185(4):1490–1496. doi:10.1016/j.juro.2010.11.045

    Article  PubMed  CAS  Google Scholar 

  19. Marra M, Salzano G, Leonetti C, Tassone P, Scarsella M, Zappavigna S, Calimeri T, Franco R, Liguori G, Cigliana G, Ascani R, La Rotonda MI, Abbruzzese A, Tagliaferri P, Caraglia M, De Rosa G (2011) Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes. Nanomedicine. doi:10.1016/j.nano.2011.03.004

    PubMed  Google Scholar 

  20. Gonyeau MJ, Yuen DW (2010) A clinical review of statins and cancer: helpful or harmful? Pharmacotherapy 30(2):177–194. doi:10.1592/phco.30.2.177

    Article  PubMed  CAS  Google Scholar 

  21. Boudreau DM, Yu O, Buist DS, Miglioretti DL (2008) Statin use and prostate cancer risk in a large population-based setting. Cancer Causes Control 19(7):767–774. doi:10.1007/s10552-008-9139-4

    Article  PubMed  Google Scholar 

  22. Soto DE, Daignault S, Sandler HM, Ray ME (2009) No effect of statins on biochemical outcomes after radiotherapy for localized prostate cancer. Urology 73(1):158–162. doi:10.1016/j.urology.2008.02.055

    Article  PubMed  Google Scholar 

  23. Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP Jr, Habel LA (2008) Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 17(1):27–36. doi:10.1002/pds.1507

    Article  PubMed  Google Scholar 

  24. Bonovas S, Filioussi K, Sitaras NM (2008) Statin use and the risk of prostate cancer: a metaanalysis of 6 randomized clinical trials and 13 observational studies. Int J Cancer 123(4):899–904. doi:10.1002/ijc.23550

    Article  PubMed  CAS  Google Scholar 

  25. Notarnicola M, Messa C, Cavallini A, Bifulco M, Tecce MF, Eletto D, Di Leo A, Montemurro S, Laezza C, Caruso MG (2004) Higher farnesyl diphosphate synthase activity in human colorectal cancer inhibition of cellular apoptosis. Oncology 67(5–6):351–358. doi:10.1159/000082918

    Article  PubMed  CAS  Google Scholar 

  26. Woo IS, Eun SY, Kim HJ, Kang ES, Lee JH, Chang KC, Kim JH, Hong SC, Seo HG (2010) Farnesyl diphosphate synthase attenuates paclitaxel-induced apoptotic cell death in human glioblastoma U87MG cells. Neurosci Lett 474(2):115–120. doi:10.1016/j.neulet.2010.03.021

    Article  PubMed  CAS  Google Scholar 

  27. Jiang F, Yang L, Cai X, Cyriac J, Shechter I, Wang Z (2001) Farnesyl diphosphate synthase is abundantly expressed and regulated by androgen in rat prostatic epithelial cells. J Steroid Biochem Mol Biol 78(2):123–130. doi:S0960-0760(01)00086-3

    Article  PubMed  CAS  Google Scholar 

  28. Li J, Herold MJ, Kimmel B, Muller I, Rincon-Orozco B, Kunzmann V, Herrmann T (2009) Reduced expression of the mevalonate pathway enzyme farnesyl pyrophosphate synthase unveils recognition of tumor cells by Vγ9Vδ2 T cells. J Immunol 182(12):8118–8124. doi:10.4049/jimmunol.0900101

    Article  PubMed  CAS  Google Scholar 

  29. Riddle MK, Lockhart AC, Sorscher SM (2010) Complete radiographic response to zoledronic acid therapy in a patient with bony metastatic urothelial carcinoma: a case report. World J Oncol 1(1):208–209

    Google Scholar 

  30. Sorscher SM, Lockhart AC (2011) Ras inhibition and the survival benefit favoring zoledronic acid compared with denosumab in patients with multiple myeloma. J Clin Oncol 29(19):2735–2736. doi:10.1200/JCO.2011.35.8333; Author reply 2736–2738

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work received external funding (SZOM-002-grant; Novartis Institutes for BioMedical Research). We thank Hannes Schramm for graphical assistance.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Urology, University Hospital Tübingen, Tübingen, Germany

    Tilman Todenhöfer, Jörg Hennenlotter, Ursula Kühs, Valentina Gerber, Georgios Gakis, Stefan Aufderklamm, Arnulf Stenzl & Christian Schwentner

  2. Department of Pathology, University Hospital Tübingen, Tübingen, Germany

    Ulrich Vogel

  3. Department of Urology, Medical School, Hannover, Germany

    Axel Merseburger

  4. Department of Urology, Diakonieklinikum, Stuttgart, Germany

    Judith Knapp

  5. Department of Urology, Eberhard–Karls University, Hoppe-Seyler Strasse 3, 72076, Tübingen, Germany

    Christian Schwentner

Authors
  1. Tilman Todenhöfer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jörg Hennenlotter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ursula Kühs
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Valentina Gerber
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Georgios Gakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ulrich Vogel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Stefan Aufderklamm
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Axel Merseburger
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Judith Knapp
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Arnulf Stenzl
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Christian Schwentner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian Schwentner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Todenhöfer, T., Hennenlotter, J., Kühs, U. et al. Altered expression of farnesyl pyrophosphate synthase in prostate cancer: evidence for a role of the mevalonate pathway in disease progression?. World J Urol 31, 345–350 (2013). https://doi.org/10.1007/s00345-012-0844-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-012-0844-y

Keywords

Search

Navigation